COHN Stock Chart & Stats
$2391.38
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,391.38 - $3,238.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$88.95B
Enterprise Value$17.14K
Total Cash (Recent Filing)$187.10M
Total Debt (Recent Filing)$427.80M
Price to Earnings (P/E)21.1
Beta-0.02
Next Earnings
Aug 13, 2026EPS Estimate
20.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.28
Shares Outstanding65,398,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.50
Price to Book (P/B)10.08
Price to Sales (P/S)8.39
P/FCF Ratio112.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,421.69Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)64.22
Revenue Forecast (FY)$29.57B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsCochlear’s consistently high gross and operating margins reflect durable pricing power and a capital‑light aftermarket mix (processors, accessories, services). These margins support reinvestment in R&D and capacity, sustaining competitive position and cash generation potential over the medium term.
Conservative Balance SheetLow leverage and strong ROE provide financial flexibility to fund capex, modular R&D and capacity expansion without stressing solvency. This conservatism reduces refinancing risk and supports strategic investments and clinical partnerships across cycles over the next 2–6 months.
Nexa Adoption & Services MomentumRapid Nexa adoption and a measurable implant unit uplift indicate durable product-led growth and higher upgrade cadence. Combined with services revenue growth, this raises recurring aftermarket streams and referral strength, bolstering medium‑term revenue resilience and lifecycle monetization.
Bears Say
Free Cash Flow DeteriorationA near‑50% drop in FCF growth materially weakens internal funding capacity for buybacks, acquisitions or extra inventory funding. Elevated working capital and strategic cloud/capex spend mean cash conversion must improve to restore flexibility and fund medium‑term growth programs.
Material FX ExposureSignificant currency sensitivity and only partial hedging leave reported earnings vulnerable to sustained FX moves. This structural exposure can depress reported profits, complicate guidance accuracy, and constrain capital allocation until hedging or natural offsets are increased.
Margin Pressure From Mix And LaunchesHigher initial COGS for new product launches and a shift toward lower‑margin emerging markets are compressing gross margins. Until scale, pricing realization and Chengdu ramp efficiencies arrive, margin recovery may be gradual, weighing on medium‑term profitability metrics.
COHN FAQ
What was Cochlear Limited’s price range in the past 12 months?
Cochlear Limited lowest stock price was $2391.38 and its highest was $3238.00 in the past 12 months.
What is Cochlear Limited’s market cap?
Cochlear Limited’s market cap is $88.95B.
When is Cochlear Limited’s upcoming earnings report date?
Cochlear Limited’s upcoming earnings report date is Aug 13, 2026 which is in 19 days.
How were Cochlear Limited’s earnings last quarter?
Cochlear Limited released its earnings results on Feb 12, 2026. The company reported $36.415 earnings per share for the quarter, missing the consensus estimate of $38.505 by -$2.09.
Is Cochlear Limited overvalued?
According to Wall Street analysts Cochlear Limited’s price is currently Undervalued.
Does Cochlear Limited pay dividends?
Cochlear Limited does not currently pay dividends.
What is Cochlear Limited’s EPS estimate?
Cochlear Limited’s EPS estimate is 20.94.
How many shares outstanding does Cochlear Limited have?
Cochlear Limited has 65,398,920 shares outstanding.
What happened to Cochlear Limited’s price movement after its last earnings report?
Cochlear Limited reported an EPS of $36.415 in its last earnings report, missing expectations of $38.505. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cochlear Limited?
Currently, no hedge funds are holding shares in MX:COHN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cochlear Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1,421.69 (― Downside)
$1,421.69 (― Downside)
Blogger Sentiment
Bullish
MX:COHN Sentiment 84%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.22%
12-Months-Change
Fundamentals
Return on Equity
2.36%
Trailing 12-Months
Asset Growth
8.00%
Trailing 12-Months
Company Description
Cochlear Limited
Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.
COHN Stock 12 Month Forecast
Average Price Target
$1,421.69